News Articles

Much-Anticipated CHTF 2017 Top 10 Products Are Unveiled SHENZHEN, China -Saturday, November 18th 2017 [ar]

(BUSINESS WIRE)-- The 19th China Hi-Tech Fair (CHTF 2017), with the theme of “Innovation-Driven Development and Supply Quality Upgrade”, is taking place from November 16 to 21 at Shenzhen Convention and Exhibition Center. On the afternoon of November 10, the CHTF 2017 Top 10 Products were...

Double Win for Vocalink at the 2017 Payments Awards LONDON -Saturday, November 18th 2017 [ar]

Vocalink, a Mastercard company, was last night awarded with the Overall Winner and the Payments Infrastructure of the Year Award at the 5th Annual Payments Awards[i] for its significant contribution to the payments sector globally. The awards recognised recent global successes for...

Wipro Launches Industry-Specific Solutions as Extensions to SAP® Leonardo CUPERTINO, Calif. & BANGALORE, India -Friday, November 17th 2017 [ar]

(BUSINESS WIRE)--Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading global information technology, consulting and business process services company, today announced the launch of industry-specific solutions on SAP® Leonardo. The first set of solutions will focus on the utilities...

Time to Market Drastically Reduced for Banks to Deploy MOTION CODE™ COLOMBES, France -Friday, November 17th 2017 [ar]

Turn-key service enabling a fast deployment of MOTION CODE™ cards for the banks MOTION CODE™ replaces the static CVV2 of the payment card with a dynamic one (BUSINESS WIRE)-- IDEMIA, the global leader in trusted identities for an increasingly digital world, today announced that...

Celgene Corporation and bluebird bio Announce bb2121 Anti-BCMA CAR-T Cell Therapy Has Been Granted Breakthrough Therapy... SUMMIT, N.J. & CAMBRIDGE, Mass. -Thursday, November 16th 2017

(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) and bluebird bio, Inc. (NASDAQ:BLUE) today announced that bb2121, a chimeric antigen receptor T-cell (CAR-T) therapy targeting b-cell maturation antigen (BCMA) in previously treated patients with multiple myeloma, has been granted Breakthrough...

Nel ASA: Enters into Exclusive Partnership with Nikola – Awarded Initial Purchase Order for Two Demo Stations OSLO, Norway -Thursday, November 16th 2017 [ar]

(BUSINESS WIRE)-- Nel ASA (Nel, OSE:NEL) has received a purchase order from Nikola Motor Company (Nikola Motor) for two demo refueling stations to provide hydrogen to Nikola’s fleet of prototype hydrogen trucks. The purchase order is the initial part of an exclusive partnership aiming at...

GSMA Provides Further Updates on Programmes at Mobile World Congress 2018 LONDON -Thursday, November 16th 2017 [ar]

(BUSINESS WIRE)-- The GSMA today announced new developments for Mobile World Congress 2018, including recently confirmed keynote speakers, as well as new exhibitors, sponsors and partners. The GSMA also provided updates for attendee experiences such as 4YFN, Women4Tech and YoMo. Mobile World...

Mopria Print Service 2.3 Unleashes New Mobile Printing Capabilities with Share-to-Print from Android Devices SAN RAMON, Calif. -Wednesday, November 15th 2017 [ar]

(BUSINESS WIRE)-- The Mopria® Alliance, a global non-profit membership organization chartered to drive industry-wide standards for mobile printing, today released Mopria Print Service 2.3, expanding mobile printing support by allowing users to print using the Share feature from many of their...

Macrogen Corp.'s Clinical NGS Laboratory Receives CAP Accreditation ROCKVILLE, Md. -Wednesday, November 15th 2017 [ar] [fr]

(BUSINESS WIRE)-- Macrogen Corp. (www.macrogenlab.com) announces that its Clinical Lab that provides clinical NGS services has been awarded accreditation by the Accreditation Committee of the College of American Pathologists (CAP) based on results of a recent on-site inspection as part of the...

IDEMIA Trials Biometric Verification Program with Royal Caribbean Cruises Ltd. and U.S. Customs and Border Protection BILLERICA, Mass. -Wednesday, November 15th 2017 [ar]

(BUSINESS WIRE)-- IDEMIA, the global leader in trusted identities for an increasingly digital world and the country’s preeminent identity-related service provider, and Royal Caribbean Cruises Ltd. (RCL) jointly announced today they have completed a trial with U.S. Customs and Border Protection...

Takeda Receives Positive CHMP Opinion for ADCETRIS® (brentuximab vedotin) for CD30-Positive Cutaneous... CAMBRIDGE, Mass. & OSAKA, Japan -Wednesday, November 15th 2017 [ar]

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the extension of the marketing authorization of ADCETRIS® (brentuximab...

Key sub-analyses of RE-DUAL PCI™ showed large reductions in the incidence of bleeding complications if... INGELHEIM, Germany -Wednesday, November 15th 2017  

Dual therapy with dabigatran consistently favourable across key sub-groups in atrial fibrillation patients following PCI with stent placement Benefits shown in sub-group analyses were consistent with overall results of the trial Data presented at AHA Scientific Sessions 2017 reinforce...

IDEMIA Technology Powering a World Premiere Free Passenger Flow at Terminal 4 Singapore Changi Airport COLOMBES, France -Wednesday, November 15th 2017 [ar]

(BUSINESS WIRE)-- IDEMIA, the global leader in trusted identities for an increasingly digital world, provides a complete passenger processing biometric system at Changi Airport Terminal 4 in Singapore. The terminal was opened on October 31, 2017. IDEMIA (formerly known as OT-Morpho) strives...

SET Award 2018: Who Are the Top Innovators in the Energy Transition? BONN, Germany & BERLIN & LONDON -Wednesday, November 15th 2017 [ar]

(BUSINESS WIRE)-- SET, an initiative by the Deutsche Energie-Agentur – the German Energy Agency (dena) – in cooperation with strategic partner, the World Energy Council, has launched the second round of the international award ‘Start Up Energy Transition’ (SET) during the annual UN...

MARAKEZ Automates Operations with Yardi Solutions CAIRO -Wednesday, November 15th 2017 [ar]  

(BUSINESS WIRE)-- MARAKEZ, a subsidiary of Fawaz Al Hokair Group, has selected Yardi Voyager® 7S to electronically manage its lease and property management process for its leading shopping mall in Cairo, Mall of Arabia. Alongside Voyager 7S, which streamlines core accounting, lease...

L&T Technology Services Limited expands its presence in Israel with the launch of a Center of Excellence (CoE) and a... TEL AVIV, Israel -Tuesday, November 14th 2017 [ar]

(BUSINESS WIRE)-- L&T Technology Services Limited (NSE: LTTS), a leading global pure-play engineering services company headquartered in India, today announced the establishment of LTTS’ Center of Excellence (CoE) in Jerusalem, Israel, thereby marking another key milestone in the firm’s...

Vocalink Powers Real-Time Payments Service in the U.S. LONDON -Tuesday, November 14th 2017 [ar]

Vocalink, a Mastercard company, supports The Clearing House today in launching a ground-breaking real-time payment system in the U.S. RTP is one of the most comprehensive real-time payment systems globally, and is set to transform the U.S. payments landscape The launch follows...

Faslodex (Fulvestrant) Receives EU Approval for the Treatment of Hormone Receptor-Positive Advanced Breast Cancer in... CAMBRIDGE, England -Tuesday, November 14th 2017

First EU approval for fulvestrant in combination with a CDK4/6 inhibitor Fulvestrant in combination with palbociclib showed progression-free survival (PFS) improvement of 4.9 months compared to combination of fulvestrant with placebo2   (BUSINESS WIRE)-- AstraZeneca today announced...

New RE-VERSE AD™ analyses provide additional insights on impact of Praxbind® (idarucizumab) in... INGELHEIM, Germany -Tuesday, November 14th 2017  

Additional analyses of patients in diverse emergency settings confirm that idarucizumab immediately reverses the anticoagulant effect of dabigatran in patients in emergency settings1,2 Sub-analyses from RE-VERSE AD™, the largest study to investigate a reversal agent for a non-vitamin K...

Jardiance® reduced risk of cardiovascular death in adults with type 2 diabetes and peripheral artery... INGELHEIM, Germany & INDIANAPOLIS -Tuesday, November 14th 2017  

Empagliflozin (marketed as Jardiance®) reduced the risk of cardiovascular death by 43 percent versus placebo in patients with type 2 diabetes and peripheral artery disease1 In a population at high risk for amputations, no increased risk in lower-limb amputation was observed with...